NCT02676830View on ClinicalTrials.gov

Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

April 30, 2015

Conditions
Dyslipidemia
Interventions
DRUG

K-312 100 mg

Single oral dose

DRUG

K-312 100 ug C14 IV

microtracer dose containing ≤37 kBq (1000 nCi) \[14C\] given as a 5-ml IV push over 2 minutes

Trial Locations (1)

Unknown

Madison

Sponsors
All Listed Sponsors
lead

Kowa Research Institute, Inc.

INDUSTRY